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Introduction 
Additives in commercial reagent red blood cells 
(RBCs) may cause discrepancies in the ABO typing of 
patients who have developed an antibody against any 
of the added substances. Neomycin and chloram- 
phenicol are bacteriostatic agents added to the 
suspending medium of reagent RBCs. Hysell et al sup(1) 
reported an antibody against neomycin, and Beattie 
et al sup(2) reported three cases of chloramphenicol 
antibody. Gillund et al sup(3) and Reid et al sup(4) have reported 
antibodies to EDTA-suspended RBCs. This paper 
describes an antibody directed against EDTA-suspended 
RBCs which was discovered when an ABO discrepancy 
was obtained using EDTA-suspended, commercially 
prepared A sub(1) and B reagent red cells. EDTA is added 
to some commercial reverse grouping cells to prevent 
lysis by anti-A or anti-B. sup(3) 
Because of an ABO discrepancy in typing the blood 
of a thirty-six-year-old woman admitted to a local 
hospital for minor surgery a sample of blood was sent 
to our reference laboratory At the hospital, RBCs were 
typed as group A, but the serum agglutinated both 
group A, and B reagent RBCs (American Dade Miami, 
FL). 
Methods and Materials 
Standard serologic methods were used throughout. sup(5) 
Group A, and B reagent RBCs were obtained from 
four different commercial suppliers: American Dade 
(Miami, FL), Gamma (Houston, TX), Ortho (Raritan, 
NJ), and Amtec Diagnostics (Conroe, TX). The con- 
centration of EDTA that produced the strongest reac- 
tions of the patient’s antibody was ascertained as 
follows. Four sets of two-fold dilutions of the patient’s 
serum were made. Four concentrations of EDTA rang- 
ing from 2-16 g/L in 0.85 percent saline were also 
prepared. To 0.1 mL of each serum dilution in each 
set was added 0.1 mL of one of the EDTA solutions. 
To each tube of serum-EDTA, 0.05 mL of a 4 percent 
suspension of group O washed red cells was added. 
The contents were mixed and immediately spun at 
3400 rpm for 30 seconds; the cells were examined for 
agglutinates and the results recorded. 
Results of Serologic Testing 
No atypical antibodies were detected in tests of the 
patient’s serum at room temperature, in LISS at 37°C, 
or in the indirect antiglobulin test. The direct 
antiglobulin test on the patient’s red cells was negative. 
Her serum was tested against unwashed group A sub(1) 
reagent red cells from four manufacturers. Results are 
shown in Table 1. Two of the four manufacturer’s 
reagent A, RBCs were agglutinated. When those cells 
were washed, reactivity was abolished. 
The supernatant fluids from reagent RBCs from the 
first and second manufacturers were removed and 
added to group O cells. The strength of agglutination 
of these modified group O RBCs, when tested with 
the patient’s serum, was equal to that observed 
originally in the reverse grouping with group A ,  
RBCs. 
Information supplied by the manufacturers estab- 
lished that EDTA was a constituent of reagents from 
the first and second manufacturers but not of reagents 
supplied by the third and fourth manufacturers. 
Titration of the patient’s serum vs group O cells 
showed the optimum concentration of EDTA to be 
between 4 and 8 g/L (Table 2 ) .  
Antibody reactivity was destroyed by DTT-treatment 
of the serum, indicating that the antibody was an IgM 
immunoglobulin. 
Discnssion 
Commercial food processors add EDTA to many 
food products to prevent oxidation, rancidity, and tex- 
ture changes. Individuals who ingest EDTA and other 
chemicals may develop antibodies to these substances. 
EDTA added to the medium of reverse grouping cells 
chelates calcium, and this inactivates complement in 
the serum that is being tested. The purpose of inac- 
tivation is to prevent hemolysis and thereby avoid 
misinterpretation of the reverse group. While only two 
manufacturers are known to add EDTA to their reverse 
grouping cells, four manufacturers are known to add 
chloramphenicol and neomycin to prolong the viabil- 
ity of the reagent red cells. All of these drugs or 
chemicals may result in reverse grouping discrepancies 
and should be considered when serologic problems 
are resolved by washing the reagent red cell. sup(1-4) 
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TECH HINTS 
MICROFILTRATION FOR CAPILLARY 
TUBE USE 
Mary N. Crawford 
Capillary tube testing requires reagents free of par- 
ticulate matter and excessive lipids. It is difficult to 
filter, by the usual methods, the small amounts that 
are suitable for this technique. A microfilter that can 
Figure 1. Improved microfilter for chrification of 
sera for capillary tube testing* 
I. 
Pipette Filter Tip 
Cut-off last " tip 
I .  
Insert pipette filter tip 
into a micro-centrifuge 
tube; then put two or 
more drops of saline 
into the pipette filter 
tip 'Assembly." 
I .  Tear off small pieces 
and pack into 
pipette filter tip. 
Wad of cotton 
Insert 'Assembly" into 
a Fisher tube and spin 
in a Fisher-type cen- 
trifuge for 5 minutes at 
7000 rpm. 
* With this apparatus, it is possible to kilter 2 - 3 drops of serum. For almost 
total recovery o f  serum. I - 2 drops of saline o r  6%, albumin should 
be spun through first and then removed. 
be assembled rapidly (2 min) and has proved useful 
for this purpose, is described. A Tampax sup(R) tampon 
(Tam Brands, Inc., Lake Success, NY) should be pulled 
apart and enough fibers torn off to pack down to a 
0.6 cm (114 inch) amount in a small 4.7 cm pipette 
filter tip (Electra Tips 620/650, Medical Laboratory 
Automation, Inc., Mt. Vernon, NY) from which the last 
0.6 cm has been cut off to enhance the flow. Approx- 
imately 1 - 2 cm of Seitz fibers should be tamped down 
on top of the Tampax sup(R) fibers. These fibers can be 
taken from the leftover Seitz material surrounding 
punched out pads in commercial filtration kits (11 or 
22 mm filter discs made for the 2 or 25 mL sized 
Boerner Centrifugal Filters distributed by Arthur H. 
Thomas Co.). The microfilter is then inserted into a 
400 L polyethylene microcentrifuge tube (MC-1 
from Analytical Lab Accessories), and two or more 
drops of serum are put into the microfilter pipette tip. 
This whole assembly is put into a 1 mL Fisher plastic 
tube for centrifugation. A hard spin, 7000 rpm for 5 
min, is necessary for passage of reagents through the 
combination of fibers, therefore a Fisher type cen- 
trifuge is helpful. For virtually total recovery of 
reagents, two drops of saline or 6 percent bovine 
albumin may first be spun through the microfilter and 
then completely removed from the microcentrifuge 
tube before centrifugation of the serum. 
This procedure is depicted in Figure 1. 
Mary N. Crawford, MU, Pearson C. Cummirr Memorial 
Iaboratory, 125 Ashwood Road, Villanova, PA 19085. 
COMMUNICATIONS 
To the Editor: 
Hooray for John Judd! By condemning' the 
description of exceptionally powerful examples of anti- 
N as anti-’N’, he has struck a blow for clarity in com- 
munication between scientists. 
If we are to succeed in understanding each other, 
it is important that we do not allow ourselves to lapse 
into jargon, or adopt loose terminology that departs 
from established conventions. The antibodies described 
in the reports by both Guizzo and Meadows2 and 
Kosanke and Behzad sup(3) were plainly examples of anti- 
N possessing a sufficient reserve of potency to give 
detectable agglutination with cells lacking N but 
possessing ‘N’: To call these antibodies anti-’N’ is surely 
similar to calling anti-A, anti-A sub(2) because it agglutinates 
A sub(2) (as well as A sub(1)) cells, or anti-D, anti-D sup(u) because it 
is capable of detecting D sup(u) (as well as D). Are we en- 
titled to call anti-A,B anti-A,? How about anti-i for an 
example of anti-I powerful enough that it requires dilu- 
tion to show no agglutination of umbilical cord cells? 
Can we think of anti-Fy sup(b) as anti-Fy sup(x) if it detects the 
weak Fy sup(b) supposedly produced by Fy sup(x)? 
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